Cited by 250Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsPlatelet Disorders and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

Edwards, Michael H., Pierangeli, Silvia, Liu, XiaoWei, Barker, John H., Anderson, Gary, Harris, E. Nigel·1997·Circulation

DOI 10.1161/01.cir.96.12.4380

Open this paper in CoChat — free account

Abstract

Background Previous studies have demonstrated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in which these antibodies have been shown to increase both the size of an induced thrombus and the duration of time in which such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus formation. Methods and Results Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt). Three control groups of mice were also studied, including mice injected with IgG-APS and then fed with placebo, as well as two other groups injected with IgG from normal human serum and fed either hydroxychloroquine or placebo. A standardized thrombogenic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thrombus measured as well as the total period of time that thrombus was present. Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo. Conclusions Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.

Integrity signals

Registry

Crossref · 10.1161/01.cir.96.12.4380

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Handbook of Experimental Immunology.
Denman, A. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,414
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
SYNDROME OF THE BLACK SWAN
Harris, E. N. (1987) · Lara D. Veeken · doi:10.1093/rheumatology/26.5.324 · Cited by 404
Self-citation
Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets.
Billah, M. M., Lapetina, E. G., & Cuatrecasas, P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69214-8 · Cited by 369
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240
Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.
Khamashta, M. A., Harris, E. N., Gharavi, A. E., Derue, G., Gil, A., Vázquez, J. J., & Hughes, G. R. V. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.10.849 · Cited by 226
Self-citation
Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome
Pierangeli, S. S., Liu, X. W., Barker, J. H., Anderson, G., & Harris, E. N. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649940 · Cited by 223
Self-citation
ANTIPHOSPHOLIPID ANTIBODIES
Harris, E. N. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02530.x · Cited by 222
Self-citation
Pulmonary Embolism and its Prophylaxis Following the Charnley Total Hip Replacement
JOHNSON, R., Green, J. R., & Charnley, J. (1977) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197709000-00015 · Cited by 179

Show all 30 references

Research works printed but not linked: 4

Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec.. 1942;82:426.
10.1161/circ.94.7.1746 · DOI
Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Med Scand.. 1962;8:214-221.
Bird H, Harkness J, Wright V. Some rheological properties of blood during antirheumatoid therapy. Pharmatherapeutica.. 1981;3:36-39.

Sorted by citations

Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Antiphospholipid syndrome
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
The Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 687
Hydroxychloroquine: From Malaria to Autoimmunity
Ben‐Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8243-x · Cited by 616
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
Rainsford, K. D., Parke, A. L., Clifford‐Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 550
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Erkan, D., Aguiar, C. L., ANDRADE, D. C. O. D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 299
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Madhavan, M. V., Bikdeli, B., Gupta, A., Jiménez, D., Burton, J., Der-Nigoghossian, C. A., Chuich, T., Nouri, S. N., Dreyfus, I., Driggin, E., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713152 · Cited by 265
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
Rand, J. H., Wu, X.-X., Quinn, A. S., Ashton, A. W., Chen, P. P., Hathcock, J. J., Andree, H. A. M., & Taatjes, D. J. (2010) · Blood · doi:10.1182/blood-2009-04-213520 · Cited by 253
Hydroxychloroquine Reverses Platelet Activation Induced by Human IgG Antiphospholipid Antibodies
Espinola, R., Ghara, A., Harris, E., & Pierangeli, S. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613033 · Cited by 240
Self-citation
Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review
Alijotas‐Reig, J., Esteve‐Valverde, E., Ferrer‐Oliveras, R., Llurba, E., & Gris, J. M. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8596-x · Cited by 236
In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody–Mediated Venous Thrombosis
Meng, H., Yalavarthi, S., Kanthi, Y. M., Mazza, L. F., Elfline, M. A., Luke, C. E., Pinsky, D. J., Henke, P. K., & Knight, J. S. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39938 · Cited by 236
Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases
Francès, C., Niang, S. O., Laffitte, E., Pelletier, F. L., Costedoat-Chalumeau, N., & Piette, J. C. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21041 · Cited by 229
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–β2-glycoprotein I complexes to phospholipid bilayers
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Antimalarial treatment may have a time‐dependent effect on lupus survival: Data from a multinational Latin American inception cohort
Shinjo, S. K., Bonfá, E., WOJDYLA, D. M., Borba, E. F., Ramírez, L. A., Scherbarth, H. R., Brenol, J. C. T., Chacón-Díaz, R., Neira, O. J., Berbotto, G. A., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27300 · Cited by 208
Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients
Petri, M. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0141-y · Cited by 206
Hydroxychloroquine: A multifaceted treatment in lupus
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Guern, V. L., & Guettrot-Imbert, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.007 · Cited by 195
Diagnosis and management of the antiphospholipid syndrome
Chaturvedi, S., & McCrae, K. R. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.07.006 · Cited by 195
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
Willis, R., Seif, A. M., McGwin, G., Martinez-Martinez, L.-A., González, E., Dang, N. N. A., Papalardo, E., LIU, J., Vilá, L., Reveille, J., et al. (2012) · Lupus · doi:10.1177/0961203312437270 · Cited by 190
Self-citation
Antiphospholipid Syndrome
Corban, M., Duarte‐García, A., McBane, R. D., Matteson, E. L., Lerman, L. O., & Lerman, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.058 · Cited by 186
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 170
The diagnosis and management of the haematologic manifestations of lupus
Velo-García, A., Castro, S. G., & Isenberg, D. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.001 · Cited by 165
The significance of autoantibodies against β2-glycoprotein I
de Groot, P. G., & Urbanus, R. T. (2012) · Blood · doi:10.1182/blood-2012-03-378646 · Cited by 146
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis
Rand, J., Xx, W., Quinn, A., & Taatjes, D. J. (2010) · Lupus · doi:10.1177/0961203310361485 · Cited by 143
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients
Schmidt‐Tanguy, A., Voswinkel, J., Henrion, D., Subra, J. F., Loufrani, L., Rohmer, V., Ifrah, N., & Belizna, C. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12363 · Cited by 132
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
Ho, K. T., Ahn, C. W., Alarcón, G. S., Baethge, B. A., Tan, F. K., Roseman, J., Bastian, H. M., Fessler, B. J., McGwin, G., Vilá, L. M., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/kei014 · Cited by 128
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
Schreiber, K. I., Breen, K. A., Cohen, H., Jacobsen, S., Middeldorp, S., Pavord, S. R., Regan, L., Roccatello, D., Robinson, S. E., Sciascia, S., et al. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1603359 · Cited by 128
Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review
Alijotas‐Reig, J., Esteve‐Valverde, E., Anunciación-Llunell, A., Marques-Soares, J. R., Pardos‐Gea, J., & Miró‐Mur, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030675 · Cited by 132
Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis
Tektonidou, M. G. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102813 · Cited by 122
HOPKINS LUPUS COHORT
Petri, M. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70135-6 · Cited by 120
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome
Belizna, C. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.006 · Cited by 118
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study
Kravvariti, E., Koutsogianni, A., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102491 · Cited by 115
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention
McMahon, M. A., Hahn, B. H., & Skaggs, B. J. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.98 · Cited by 115
Antiphospholipid Antibodies as a Cause of Pulmonary Capillaritis and Diffuse Alveolar Hemorrhage: A Case Series and Literature Review
Deane, K. D., & West, S. G. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.05.006 · Cited by 113
Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment
Tong, M., Viall, C. A., & Chamley, L. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu049 · Cited by 112
Antiphospholipid Syndrome during pregnancy: the state of the art.
Prima, F. A. F. D., Valenti, O., Hyseni, E., Giorgio, E., Faraci, M., Renda, E., Domenico, R. D., & Monte, S. (2011) · PubMed Central · Cited by 111
Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls
Bultink, I. E. M., de Vries, F., van Vollenhoven, R., & Lalmohamed, A. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa267 · Cited by 93
Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies
Pierangeli, S. S., Vega-Ostertag, M. E., & Harris, E. N. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.031 · Cited by 94
Self-citation
Platelet‐derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice
Dyer, M., Alexander, W., Hassoune, A., Chen, Q., Brzóska, T., Alvikas, J., Liu, Y., Haldeman, S., Plautz, W. E., Loughran, P., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14563 · Cited by 89
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository
Sevim, E., Zisa, D., Andrade, D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, H. M., Zamorano, M. A. A., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24468 · Cited by 88
Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms
Pierangeli, S. S., Chen, P. P., & González, E. B. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.moh.0000239710.47921.d2 · Cited by 87
Self-citation
Thrombosis in Systemic Lupus Erythematosus: A Review Article
Al-Homood, I. A. (2012) · ISRN Rheumatology · doi:10.5402/2012/428269 · Cited by 86
Atherosclerosis in Systemic Lupus Erythematosus
Stojan, G., & Petri, M. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829dd857 · Cited by 86
Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression
Wu, X.-X., Guller, S. M., & Rand, J. H. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.064 · Cited by 84
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 83
Cardiovascular disease in lupus
Knight, J. S., & Kaplan, M. J. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328363eba3 · Cited by 84
Hydroxychloroquine: the cornerstone of lupus therapy
Ruiz‐Irastorza, G., & Khamashta, M. A. (2008) · Lupus · doi:10.1177/0961203307086643 · Cited by 76
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction
Miranda, S., Billoir, P., Damian, L., Thiébaut, P., Schapman, D., le Besnerais, M., Jouen, F., Galas, L., Levesque, H., Cam‐Duchez, V. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212614 · Cited by 74
Guidelines on the investigation and management of antiphospholipid syndrome
Arachchillage, D. J., Platton, S., Hickey, K. P., Chu, J., Pickering, M. C., Sommerville, P., MacCallum, P., & Breen, K. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19635 · Cited by 77
Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus.
Mok, M. Y., Chan, E. Y. T., Fong, D., Leung, K. F. S., Wong, W. S., & Lau, C. S. (2005) · PubMed · Cited by 74
Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?
MEKINIAN, A., Costedoat-Chalumeau, N., MASSEAU, A., Tincani, A., Caroli, S. D., Alijotas‐Reig, J., Ruffatti, A., Ambrožič, A., Botta, A., Guern, V. L., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.040 · Cited by 74
ApoE−/−Fas−/− C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia
Feng, X., Li, H., Rumbin, A. A., Wang, X., Cava, A. L., Brechtelsbauer, K., Castellani, L. W., Witztum, J. L., Lusis, A. J., & Tsao, B. P. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600512-jlr200 · Cited by 73
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Hall, F. C., & Dalbeth, N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei012 · Cited by 71
Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies
Comarmond, C., & Cacoub, P. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.12.006 · Cited by 69
2013 Update: Hopkins Lupus Cohort
Fangtham, M., & Petri, M. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0360-0 · Cited by 69
Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management
Alijotas‐Reig, J. (2012) · Lupus · doi:10.1177/0961203312465782 · Cited by 69
Management of Thrombosis in the Antiphospholipid Syndrome
Khamashta, M. A. (1996) · Lupus · doi:10.1177/096120339600500527 · Cited by 69
Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches
Chighizola, C. B., Ubiali, T., & Meroni, P. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/951424 · Cited by 67
Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease
Erkan, D., Unlu, O., Sciascia, S., Belmont, H. M., Branch, D. W., Cuadrado, M. J., Gonzalez, E., Knight, J. S., Uthman, I., Willis, R., et al. (2018) · Lupus · doi:10.1177/0961203317724219 · Cited by 66
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
MOREUIL, C. D., Alavi, Z., & Pasquier, É. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14131 · Cited by 67
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 66
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach
Ambati, A., Knight, J. S., & Zuo, Y. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000932 · Cited by 68
“Black swan in the kidney”: Renal involvement in the antiphospholipid antibody syndrome
Nzerue, C. M., Hewan-Lowe, K. O., Pierangeli, S. S., & Harris, E. N. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00500.x · Cited by 63
Self-citation
Antiphospholipid syndrome and kidney disease
Bienaimé, F., Legendre, C. M., Terzi, F., & Canaud, G. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.026 · Cited by 62
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository
Ünlü, O., Erkan, D., Barbhaiya, M., ANDRADE, D. C. O. D., Nascimento, I. S., Rosa, R. F., Banzato, A., Pengo, V., Ugarte, A., Gerosa, M., et al. (2018) · Arthritis Care & Research · doi:10.1002/acr.23584 · Cited by 60
An update on the management of antiphospholipid syndrome
Rodziewicz, M., & D’Cruz, D. P. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20910855 · Cited by 62
Experimental Thrombosis and Antiphospholipid Antibodies: New Insights
Pierangeli, S. S., Gharavi, A. E., & Harris, E. N. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0420 · Cited by 56
Self-citation
The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies
Schreiber, K. I., Breen, K. A., Parmar, K., Rand, J. H., Wu, X.-X., & Hunt, B. J. (2017) · Rheumatology · doi:10.1093/rheumatology/kex378 · Cited by 55
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
Arachchillage, D. J., Laffan, M., & Pericleous, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021331 · Cited by 55
Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort
Petri, M. (2005) · Lupus · doi:10.1191/0961203305lu2230xx · Cited by 52
Management of Antiphospholipid Syndrome in Pregnancy
Petri, M., & Qazi, U. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.007 · Cited by 50
Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts
Capozzi, A., Manganelli, V., Riitano, G., Caissutti, D., Longo, A., Garofalo, T., Sorice, M., & Misasi, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030891 · Cited by 49
Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies
Choojitarom, K., Verasertniyom, O., Totemchokchyakarn, K., Nantiruj, K., Sumethkul, V., & Janwityanujit, S. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0721-z · Cited by 49
Emerging Therapies in Antiphospholipid Syndrome
ANDRADE, D. C. O. D., & Tektonidou, M. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0566-z · Cited by 48
Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future
Mehdi, A. A., Uthman, I. W., & Khamashta, M. A. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02281.x · Cited by 47
Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention
Reiss, A. B., Jacob, B., Ahmed, S., Carsons, S. E., & DeLeon, J. R. (2021) · Inflammation · doi:10.1007/s10753-021-01455-6 · Cited by 48
Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome
Stoots, S. A., Lief, L., & Erkan, D. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0852-7 · Cited by 46
Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever
Million, M., Thuny, F., Bardin, N., Angelakis, E., Edouard, S., Bessis, S., Guimard, T., Weitten, T., Martin-Barbaz, F., Texereau, M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ956 · Cited by 44
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 44
Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome
Erkan, D. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41891 · Cited by 44
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome
Khamashta, M. A. (1998) · Lupus · doi:10.1177/096120339800700235 · Cited by 42
Primary Prevention of Thrombosis in Subjects with Positive Antiphospholipid Antibodies
Khamashta, M. A. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0421 · Cited by 42
Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests
Harris, E. N., Pierangeli, S., & Gharavi, A. E. (1998) · Lupus · doi:10.1177/096120339800700232 · Cited by 41
Self-citation
New Treatments for Antiphospholipid Syndrome
Erkan, D., & Lockshin, M. D. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.004 · Cited by 39
Cardiovascular risk assessment and treatment in systemic lupus erythematosus
Elliott, J. R., & Manzi, S. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.03.005 · Cited by 38
Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease.
Palomo, I. F., Segovia, F., Ortega, C., & Pierangeli, S. S. (2009) · PubMed · Cited by 38
Self-citation
Platelets and Thrombotic Antiphospholipid Syndrome
Tohidi‐Esfahani, I., Mittal, P., Isenberg, D. A., Cohen, H., & Efthymiou, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030741 · Cited by 40
Pathophysiological mechanisms in antiphospholipid syndrome
Harper, B. E., Willis, R., & Pierangeli, S. S. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.9 · Cited by 37
Self-citation
Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia
Pareek, A. K., Chandurkar, N. B., Thulaseedharan, N. K., Legha, R., Agarwal, M., Mathur, S., Salkar, H. R., Pednekar, S., Pai, V., Sriram, U., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1087989 · Cited by 36
Antiphospholipid syndrome: a clinical perspective
Zuo, Y., Shi, H., Li, C., & Knight, J. S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000705 · Cited by 39
Treatment of antiphospholipid syndrome beyond anticoagulation
Dobrowolski, C., & Erkan, D. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.001 · Cited by 36
Antimalarial therapy: a panacea for mild lupus?
D’Cruz, D. P. (2001) · Lupus · doi:10.1191/096120301669779293 · Cited by 35
New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations
Roubey, R. A. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11332 · Cited by 35
Catastrophic antiphospholipid syndrome and pregnancy
Silver, R. M. (2017) · Seminars in Perinatology · doi:10.1053/j.semperi.2017.11.006 · Cited by 35
Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
Danza, Ã., Graña, D., Goñi, M., Vargas, A., & Ruiz‐Irastorza, G. (2016) · Revista médica de Chile · doi:10.4067/s0034-98872016000200012 · Cited by 33
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
Pasquier, É., Martin, L. D. S., Marhic, G., Chauleur, C., Bohec, C., Bretelle, F., Lejeune, V., Hannigsberg, J., Plu‐Bureau, G., Cogulet, V., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025649 · Cited by 33

Authors: Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N.
Affiliations: University of Louisville (US)
ORCID: Liu, XiaoWei
Barker, John H.
Anderson, Gary
Harris, E. Nigel
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-12-16
Volume: 96
Issue: 12
Pages: 4380-4384
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.96.12.4380
OpenAlex: W2001976130
Cited by: 250
References: 30
Citations by year: 2026: 3 · 2025: 1 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 14 · 2015: 10 · 2014: 16 · 2013: 11 · 2012: 10
FWCI: 2.01
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: hydroxychloroquine, antiphospholipid syndrome, anticardiolipin antibodies, antiphospholipid antibodies, thrombosis, thrombus size, thrombogenicity, IgG, thromboprophylaxis
MeSH terms: Animals, Dose-Response Relationship, Drug, Humans, Hydroxychloroquine, Immunoglobulin G, Male, Mice, Inbred Strains, Reference Values, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks